Search results for "From ACP Journal Club"
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
https://diabetes.acponline.org/archives/2018/08/10/7.htm
10 Aug 2018
Metformin use was linked to hospitalization for acidosis at 6 y only in patients with eGFR
The results are in accordance with guidelines and regulatory policy recommendations that have extended use of metformin to individuals with mild to moderate kidney impairment, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/11/09/6.htm
9 Nov 2018
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/08/10/8.htm
10 Aug 2018
Some glucose-lowering drugs reduce HbA1c more than others
A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/8.htm
11 Dec 2020
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
The results of the CANVAS trial are promising for patients with type 2 diabetes mellitus (T2DM) and early chronic kidney disease, but ongoing research should provide more convincing data, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/03/08/6.htm
8 Mar 2019
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia
Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2016/09/16/5.htm
16 Sep 2016
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022
Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes
An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
https://diabetes.acponline.org/archives/2019/06/14/6.htm
14 Jun 2019